Factors associated with early adherence to tiotropium in chronic obstructive pulmonary disease

Chronic Respiratory Disease

Volumn 10, Issue 1, 2013, Pages 11-18

  Laforest, Laurent ^a   Licaj, Idlir ^a   Devouassoux, Gilles ^b   Hartwig, Susanne ^a   Marvalin, Serge ^c   Van Ganse, Eric ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c Direction Régionale du Service Médical Rhône Alpes   (France)

Author keywords

healthcare claims databases; management; quality of care; Therapy discontinuation; tiotropium

Indexed keywords

RESPIRATORY TRACT AGENT; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DATA BASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FRANCE; GENERAL PRACTITIONER; HOSPITAL PHYSICIAN; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOCIAL SECURITY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; FEMALE; FRANCE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT DROPOUTS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOM ALLOCATION; RISK FACTORS; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84873825794     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972312464245     Document Type: Article

References (23)

1. Fuhrman C, Delmas MC. Pour le groupe épidémiologie et recherche clinique de la SPLF. (Epidemiology of chronic obstructive pulmonary disease in France). Rev Mal Respir. 2010 ; 27 (French). 160-168
2. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006 ; 28: 1245-1257
3. Global initiative for chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. Global initiative for chronic Obstructive Lung Disease (GOLD),http://www.goldcopd.org/(2011, accessed October 2010).
4. Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2008 ; 42: 1832-1842
5. Cooke M.. Cost consciousness in patient care. What is medical education's responsibility?. N Eng J Med. 2010 ; 362: 1253-1255
6. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with global initiative for chronic obstructive lung disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011 ; 27: 1425-1429
7. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007 ; 101: 1398-1405
8. Cramer JA, Bradley-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007 ; 14: 25-29
9. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006 ; 15: 565-574
10. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008 ; 63: 831-838
11. Laforest L, Denis F, Van Ganse E, et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010 ; 19: 148-154
12. Turner J, Wright E, Mendella L, Anthonisen N.. Predictors of patient adherence to long-term home nebulizer therapy for COPD. The IPPB study group. Intermittent positive pressure breathing. Chest. 1995 ; 108: 394-400
13. Lau HS, Beuning KS, Postma-Lim E, Klein-Beernink L, de Boer A, Porsius AJ. Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharm World Sci. 1996 ; 18: 63 68
14. Garcia-Aymerich J, Escarrabill J., Marrades RM, Monso E., Barreiro E, Anto JM. EFRAM investigators. differences in COPD care among doctors who control the disease: general practitioner vs. pneumologist. Respir Med. 2006 ; 100: 332-339
15. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest. 2005 ; 128: 3198-3204
16. Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL. Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med. 1998 ; 157: 1810-1817
17. Rand CS, Nides M, Cowles MK, Wise RA, Connett J.. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1995 ; 152: 580-588
18. Barr RG, Somers SC, Speizer FE, Camargo CA. Patient factors and medication guideline adherence among older women with asthma. Arch Intern Med. 2002 ; 162: 761-768
19. Corden ZM, Bosley CM, Rees PJ, Cochrane GM. Home nebulized therapy for patients with COPD: patient compliance with treatment and its relation to quality of life. Chest. 1997 ; 112: 1278-1282
20. George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2007 ; 2: 253-262
21. Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006 ; 118: 899-904
22. Krigsman K, Moen J, Nilsson JL, Ring L. Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period. J Clin Pharm Ther. 2007 ; 32: 603-611
23. Halpern R, Baker CL, Su J, Woodruff KB, Paulose-Ram R, Porter V, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence. 2011 ; 5: 375-388